Lafleur Godfrey buys $5,978,652 stake in Hologic (HOLX)

Hologic (HOLX) : Lafleur Godfrey scooped up 10,880 additional shares in Hologic during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 10, 2016. The investment management firm now holds a total of 154,567 shares of Hologic which is valued at $5,978,652.Hologic makes up approximately 1.69% of Lafleur Godfrey’s portfolio.

Other Hedge Funds, Including , Renaissance Group reduced its stake in HOLX by selling 47,423 shares or 5.7% in the most recent quarter. The Hedge Fund company now holds 783,867 shares of HOLX which is valued at $30,319,976. Hologic makes up approx 1.22% of Renaissance Group’s portfolio.Glenmede Trust Co Na boosted its stake in HOLX in the latest quarter, The investment management firm added 718,213 additional shares and now holds a total of 736,923 shares of Hologic which is valued at $28,717,889. Hologic makes up approx 0.17% of Glenmede Trust Co Na’s portfolio.Trillium Asset Management reduced its stake in HOLX by selling 3,242 shares or 0.65% in the most recent quarter. The Hedge Fund company now holds 495,233 shares of HOLX which is valued at $19,061,518. Hologic makes up approx 1.20% of Trillium Asset Management’s portfolio. Conning sold out all of its stake in HOLX during the most recent quarter. The investment firm sold 10,276 shares of HOLX which is valued $382,267.

Hologic closed down -0.04 points or -0.10% at $38.34 with 23,49,173 shares getting traded on Friday. Post opening the session at $38.34, the shares hit an intraday low of $38.175 and an intraday high of $38.46 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Hologic reported $0.51 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.48. The company had revenue of $717.40 million for the quarter, compared to analysts expectations of $703.38 million. The company’s revenue was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.43 EPS.

Many Wall Street Analysts have commented on Hologic. Company shares were Reiterated by RBC Capital Mkts on Aug 1, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 39 from a previous price target of $37 .

Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Company’s business units are focused on diagnostics breast health GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Hologic - Is it time to Sell?

Top Brokerage Firms are advising their investors on Hologic. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.